Bravo Multinational Inc (BRVO)

[snakess]

to be released recommendation on ELGL on Jan 16 via WSB publication which reaches 12,000 since now brvo and elgl are mating it should be noted!
Wall Street's Best was The Cabot letter and prior Dick Davis Digest

See small blip


Our stock pick for 2019 was Arrowhead Pharmaceuticals ARWR ( $15.00). The company develops
medicines that treat intractable diseases by silencing the genes that cause them. Using a broad
array of RNA chemistry and its new TRIM (tm) Platform mode of delivery, ARWR therapies trigger
RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. During
2019 the company of course has been very successful in various treatments and currently has various
test drugs in FDA phases. Recently the company raises $270 million in 2-3 days. The company is now
in a new league for research, development and new drug therapy. From WSB January 2019 stock pick
of year publication, "we believe because of all milestones that will be met during 2019, that the share
price could easily double or triple!" Well, ARWR is currently trading at $65. This results in a 330% gain
for the year!! During 2020 ARWR has the potential to trade at $100.00/sh. Of course PROFIT is always
a motive for investing.
A little history concerning out involvement in ARWR. We first recommended ARWR many years ago @
around $5 only to see it run up to $8+ and then crash to $2.00/sh where we re-recommended once
again only to see it run up $15.00/sh where we recommended in this publication last January 2019.

The lesson learned: Sometimes because of "black swans" stocks don't always work like clockwork and
demand staying power even though the financial pain can be swift and painful until the Unicorns come
back to the pasture.

We recommended HEMA @.44 as our stock pick for January 2016 within this publication. HEMA is a
global leader in the customization of human-derived biological products and services for biomedical
research, drug discovery and cellular therapy process development. Fast forward to December 16th 2019
when Charles River Laboratories announces the acquisition of HEMA for $25.40/sh! This equals 58X
your investment! Need we say anymore?

STOCK PICK FOR THE YEAR 2020

PREDICTIVE TECHNOLOGY GROUP (PRED~.77)

PRED is a therapeutics and life sciences company, is a leader in the use of data analytics for disease
identification and subsequent therapeutic intervention through unique gene-based diagnostics, biotechnology
treatments and companion therapeutics.
We first recommended PRED via http://www.saadvisory.com within our April 2019 email alert @ $2.13. The
stock proceeded to shoot up to $7.00/sh and started to correct to around $4.00/sh when we recommended
PRED as our mid-year stock pick for 2019.
From that point on the "black swans" attacked and PRED did a swan dive! A sleazy research firm (HB)
did a hit piece on the company, which in turn allowed a swarm of short sellers and naked short sellers to
attack with a vengeance and began the slow bleed. At that time PRED had applied for NASDAQ listing and
because of listing guidelines the company was placed in a lengthy quiet period. This only hurt the stock even
more. Since there has been limited news that created an upside catalyst~ the stock has drifted. For the past
few months that tax selling has surely damaged shareholder confidence. We have not been shaken!

Fast forward to today, PRED is 10X the company that was introduced some 9 months ago!
Here is a list of reasons why PRED should be bought with a very large shovel!

1. PRED engaged LIFESCI Partners as a communications partner.
2. Noted director of Predictive Labs receives award for work done on Endometriosis .
3. PRED engages CLSA Capital, a CITIC Securities company, to support product launches
into China's rapidly growing women's Health and Fertility market.
4. PRED launches FERTILITYdx (tm)~ A Genetic testing service now available to identify
causes of infertility and guide personalized fertility treatments.
5. PRED announces commercialization and full market availability of ARTGUIDE (tm). The
first integrated, DNA-based test that evaluates the risk for ENDOMETRIOSIS and other
genetic causes of infertility in women.
6. PRED not only has introduced this product within the USA, but has plans to introduce this
product into China. Endometriosis is a large problem in China ( population 1.5 billion ).
7. PRED announces the launch of PGxPLUS(tm) Pharmacogenomic test that is being marketed
to pain clinics for patients with chronic pain. The test indicates the best method for pain
reduction using proper therapies.
8. PRED announces collaboration with the Preeclampsia Foundation ( involvement with the Bill Gates
Foundation).
9. PRED recently reached 11 consecutive Q's of revenue growth. To date the majority of business
revenue has been generated from human cell and tissue products (HCT/Ps) into the bio-pharmaceutical
market.
10. Recently, the company has actively pursuing a strong business relationship in China. We anticipate
fruit to be harvested from this endeavor.
11. We believe that other acquisitions within the USA are being considered.
12. PRED will receive NASDAQ listing once a certain price threshold has been met.
13. PRED has a management team and a board of Director's that equals any Fortune 100 Company!!
Please review the Bio's of this team!
14. PRED has a collaboration agreement with a corporate giant, "Thermo Fisher (TMO).
15. PRED has a auditing agreement with a top tier firm, Doloitte Touche.
16. PRED has a huge horde of patents approved or pending.
17. PRED has the largest genetic library in the World.
18. PRED's law firm is a top tier Biotech/merger (Wilson Sonsini).

We could go on and on, but interested investors can visit their website. Even though the share price
has fallen dramatically from our initial recommended price~ We have not lost faith in this cutting edge
Biotech/Genetic company. PRED is still trading in the "pinks" but has received "penny stock exempt status"!
This means institutional investors can purchase PRED shares at current levels.
At the current price of .77 one can buy almost 6X as many shares as when we first recommended PRED at
$4.00.
PRED is our stock pick for 2020. We honestly believe that if all the "ducks" line up as we anticipate that
the reward could easily be 10-15X your current investment!

Sometimes the stocks have a tendency to not follow a spelled out script and this is when the patient investor
must wait for the "unicorns" to come over the hill! We rate PRED with our strongest speculative BUY
recommendation at currently depressed and oversold levels.


SPECULATIVE PENNY STOCK RECOMMENDATION FOR 2020
ELEMENT GLOBAL (ELGL~.15)
Upon visiting their website and review all documents within and read the press ~you
will see why we have chosen ELGL as our penny stock for 2020! The website address:
http://www.elementglobal.com We truly believe that events during the next few
months and beyond that ELGL has the potential to 10-15X your investment. We know
that it trades on the pinks, but with time things change. We rated ELGL with a strong
speculative buy at current levels for dramatic price appreciation during 2020.

Editor since 1984
William Velmer
http://www.saadvisory.com
[e-mail]
949 922 9986
sign up for free email alert
we also have paid services